Abstract:<p></p><p>Phosphodiesterases(PDEs) are vital in signal transduction, specificallyby hydrolyzing cAMP and cGMP. Within the PDE family, PDE10A is notablefor its prominence in the striatum and its regulatory function overneurotransmitters in medium-spiny neurons. Given the dopamine deficiencyin Parkinson’s disease (PD) that affects striatal pathways,PDE10A inhibitors could offer therapeutic benefits by modulating D1and D2 receptor signaling. This study was motivated by the successfulhistory of quinazoline/quinazoline scaffolds in the inhibition ofPDE10A. This study involved detailed in silico evaluationsthrough docking followed by pharmacological, pharmacophoric, and pharmacokineticanalyses, prioritizing central nervous system (CNS)-active drug criteria.Seven cyclic peptides, those featuring the quinazoline/quinazolinemoiety at both termini, exhibited notably enhanced docking scorescompared to those of the remaining alkaloids within the screened library.We identified 7 quinolines and 1 quinazoline including Lepadin G,Aspernigerin, CJ-13536, Aurachin A, 2-Undecyl-4(1H)-quinolone, Huajiaosimuline 3-Prenyl-4-prenyloxyquinolin-2-one,and Isaindigotone that followed the standard CNS active drug criteria.The dominant quinoline ring in our study and its related quinazolinewere central to our evaluations; therefore, the pharmacophoric featuresof these scaffolds were highlighted. The top alkaloids met all CNS-activedrug properties; while nonmutagenic and without PAINS alerts, manyindicated potential hepatotoxicity. Among the compounds, Huajiaosimulinewas particularly significant due to its alignment with lead-likenessand CNS-active criteria. Aspernigerin demonstrated its affinity fornumerous dopamine receptors, which signifies its potential to alterdopaminergic neurotransmission that is directly related to PD. Interestingly,the majority of these alkaloids had biological targets primarily associatedwith G protein-coupled receptors, critical in PD pathophysiology.They exhibit superior excretion parameters and toxicity end-pointscompared to the standard. Notably, selected alkaloids demonstratedstability in the binding pocket of PDE10A according to the moleculardynamic simulation results. Our findings emphasize the potential ofthese alkaloids as PDE10A inhibitors. Further experimental studiesmay be necessary to confirm their actual potency in inhibiting PDE10Abefore exploring their therapeutic potential in PD.</p>

IN SILICO APPROACHES ON PHENYLALANINE HYDROXYLASE INHIBITOR-RELATED COMPOUNDS USED IN PARKINSON’S DISEASE TREATMENT

Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]carbamic Acid with Tyrosine Hydroxylase.

Identification of Novel Quinolone and Quinazoline Alkaloids as Phosphodiesterase 10A Inhibitors for Parkinson’s Disease through a Computational Approach

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Structure and Ligand Based Virtual Screening and MPO Topological Analysis of Triazolo Thiadiazepine-fused Coumarin Derivatives as Anti-Parkinson Drug Candidates

Identification and Optimization of Nitrophenolic Analogues As Dopamine Metabolic Enzyme Inhibitors for the Treatment of Parkinson’s Disease

Insights into dietary phytochemicals targeting Parkinson's disease key genes and pathways: A network pharmacology approach

Insights of structure-based virtual screening and MPO-based SAR analysis of berberine-benzimidazole derivatives against Parkinson disease

Alchemical Design of Pharmacological Chaperones with Higher Affinity for Phenylalanine Hydroxylase

In silico Evaluation of the Feasibility of Magnolia officinalis Electronshuttling Compounds as Parkinson’s Disease Remedy

Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A2A Receptors for the Treatment of Parkinson's Disease

The identification of c-Abl inhibitors as potential agents for Parkinson's disease: a preliminary in silico approach

Computational Study of Human Tyrosine Hydroxylase Mutants to Uphold [4-(Propan-2-yl) Phenyl]Carbamic Acid As a Potential Inhibitor.

Discovery of Indolylpiperazinylpyrimidines with Dual-Target Profiles at Adenosine A2A and Dopamine D2 Receptors for Parkinson's Disease Treatment.

Understanding ligands driven mechanism of wild and mutant aryl hydrocarbon receptor in presence of phytochemicals combating Parkinson’s disease: an in silico and in vivo study

Computational Insights into Chromene/pyran Derivatives: Molecular Docking, ADMET Studies, DFT Calculations, and MD Simulations as Promising Candidates for Parkinson's Disease

Optimization of N -Phenylpropenoyl- l -amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease

Enhancing Monoamine Oxidase B Inhibitory Activity Via Chiral Fluorination: Structure-activity Relationship, Biological Evaluation, and Molecular Docking Study.

System biology-based assessment of the molecular mechanism of IMPHY000797 in Parkinson's disease: a network pharmacology and in-silico evaluation

Optimization of N-Phenylpropenoyl-l-amino Acids As Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson's Disease.

Network analysis and molecular modeling studies of pinocembrin a bioactive phytochemical of Dodonaea viscosa against Parkinson's disease